Gimeracil CAS 103766-25-2: Enhancing Cancer Treatment Efficacy
Discover the critical role of Gimeracil in oncology and pharmaceutical synthesis. Learn how this DPYD inhibitor boosts chemotherapy effectiveness and its applications in fighting various cancers.
Get a Quote & SampleProduct Core Value
Gimeracil
As a leading manufacturer and supplier in China, we offer Gimeracil (CAS 103766-25-2), a crucial pyridine derivative with significant antitumor activity. Gimeracil is vital for enhancing the efficacy of fluoropyrimidines, such as 5-fluorouracil (5-FU), by acting as a potent dihydropyrimidine dehydrogenase (DPYD) inhibitor. This mechanism prevents the rapid degradation of 5-FU, allowing for prolonged therapeutic concentrations and improved treatment outcomes in various cancers.
- Explore the benefits of Gimeracil CAS 103766-25-2 in cancer treatment, providing a more sustained effect against malignant cells.
- Understand the Gimeracil DPYD inhibitor mechanism, which is key to its therapeutic success.
- Learn about Gimeracil's application in enhancing 5-FU efficacy, a cornerstone in many chemotherapy regimens.
- Investigate the diverse Gimeracil synthesis and applications, highlighting its importance as a versatile pharmaceutical intermediate.
Advantages Offered by Gimeracil
Enhanced Chemotherapy Efficacy
Leverage Gimeracil's ability to inhibit DPYD, a critical step in the Gimeracil in cancer treatment, leading to better patient responses.
Radiotherapy Sensitization
Benefit from Gimeracil's role in potentially sensitizing cancer cells to radiotherapy by impacting DNA repair mechanisms, a key aspect of its anticancer properties.
Improved Drug Concentration
Achieve higher and more sustained therapeutic levels of 5-FU, a direct result of using Gimeracil to enhance 5-FU efficacy.
Key Applications
Antineoplastic Therapy Adjunct
Gimeracil serves as a crucial adjunct in antineoplastic therapies, significantly improving the therapeutic index of cytotoxic agents.
Cancer Treatment
Its application in Gimeracil in cancer treatment extends to various malignancies, including gastric, colorectal, and lung cancers.
Drug Synthesis
As a Gimeracil pharmaceutical intermediate, it is fundamental in the synthesis pathways of advanced oncology drugs.
DNA Repair Inhibition
Gimeracil's ability to inhibit DNA repair mechanisms opens avenues for novel combination therapies with radiotherapy.